Identification of GSK625433: A novel clinical candidate for the treatment of hepatitis C.

David Haigh, E.M. Amphlett, G.S. Bravi, H. Bright, V. Chung, C.L. Chambers, A.G. Cheasty, M.A. Convery, M.R. Ellis, R. Fenwick, D.F. Gray, C.D. Hartley, P.D. Howes, R.L. Jarvest, K.J. Medhurst, A. Mehbob, D. Mesogiti, F. Mirzai, F. Nerozzi, N.R. ParryN. Roughley, T. Skarzynski, M.J. Slater, S.A. Smith, R. Stocker, C.J. Theobald, P.J. Thomas, P.A. Thommes, J.H. Thorpe, C.S. Wilkinson, E. Williams

Research output: Contribution to journalArticlepeer-review


Hepatitis C is an infection of the liver caused by a pos. single-stranded RNA virus (HCV) which affects 170 million people worldwide. It is responsible for 40-60% of all liver disease and is the major cause of liver transplants in the United States. The HCV NS5B gene encodes the viral RNA-dependent RNA polymerase which is essential for HCV replication. We have previously reported the identification of acylpyrrolidines as potent inhibitors of NS5B; however their activity is attenuated against genotype 1a. The design of improved broader-spectrum compds., capable of effective inhibition of both genotypes 1b and 1a is desirable. An understanding of the binding site and genotype sequence differences was utilized to design compds. with greatly enhanced genotype 1a and 1b potency. Our studies led to the identification of GSK625433, a potent, homochiral inhibitor of these HCV genotypes in both enzyme and sub-genomic replicon cell-based assays. GSK625433 has a good pharmacokinetic profile in pre-clin. animal species, enabling progression to clin. evaluation.
Original languageEnglish
Pages (from-to)MEDI-015-MEDI-015
Number of pages1
JournalAbstracts Of Papers Of The American Chemical Society
Publication statusPublished - 2007


Dive into the research topics of 'Identification of GSK625433: A novel clinical candidate for the treatment of hepatitis C.'. Together they form a unique fingerprint.

Cite this